Lysogene Aktie [WKN DE: A2DLMU / ISIN: FR0013233475]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Lysogene SA

16.02.23		Lysogene Announces the Extension of Deadline for the Submission of Offers (Businesswire)
25.01.23		Lysogene: Conversion of the Safeguard Proceedings Into Reorganization Proceedings (Businesswire)
06.01.23		Lysogene: Launch of a Process to Find Buyers or Investors and Request for Conversion of Safeguard Proceedings Into Reorganization Proceedings (Businesswire)
29.11.22		Lysogene Provides Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study (Businesswire)
18.11.22		Lysogene to Provide Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study and Host Webcast on Wednesday, November 23, 2022 (Businesswire)
07.07.22		Lysogene Provides Additional Update on AAVance Phase 2/3 Gene Therapy Clinical Trial with LYS-SAF302 in children with MPS IIIA (Businesswire)
18.05.22		Lysogene Provides Clinical Update on AAVance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of MPS IIIA at the 25th Annual ASGCT Meeting (Businesswire)
24.02.22		Lysogene Provides Update on Efficacy, Safety and Timelines of the AAVance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of MPSIIIA (Businesswire)
11.02.22		Lysogene Reports Additional Positive Biomarker Data With LYS-SAF302 and Favorable Safety Data With LYS-GM101 Presented at the WORLDSymposium™ 2022 (Businesswire)
07.02.22		Lysogene Provides Medical Update (Businesswire)
13.01.22		Lysogene Announces Termination of License Agreement With Sarepta for LYS-SAF302 Program, Regaining Global Commercial Rights (Businesswire)
08.07.21		Lysogene Announces FDA Fast Track Designation for LYS-GM101 Gene Therapy for the Treatment of GM1 Gangliosidosis (Businesswire)
11.06.21		Lysogene Enters into an Exclusive Worldwide License Agreement with SATT Conectus for a Gene Therapy Candidate for the Treatment of the Fragile X Syndrome (Businesswire)
09.06.21		Lysogene Announces First Patient Dosed with LYS-GM101 Investigational Gene Therapy for the Treatment of GM1 Gangliosidosis (Businesswire)
15.02.21		Lysogene Reports LYS-SAF302 Biomarker Data Presented at the WORLDSymposium™ 2021 (Businesswire)
12.02.21		Lysogene Receives FDA Clearance of Investigational New Drug Application to Initiate the Gene Therapy Clinical Trial in the US with LYS-GM101 for the Treatment of GM1 Gangliosidosis (Businesswire)
11.01.21		Lysogene Receives MHRA and Research Ethics Committee Approvals to Initiate the Gene Therapy Clinical Trial in the UK with LYS-GM101 for the Treatment of GM1 Gangliosidosis (Businesswire)
28.12.20		Lysogene Reports Positive Biomarker Data With LYS-SAF302 (Businesswire)
18.12.20		Lysogene Announces a Change in the Organization of KGA, Minority Shareholder of Lysogene (Businesswire)
19.11.20		Lysogene Reports its Cash Position as of 30 September 2020 (Businesswire)
15.10.20		Lysogene Provides Update on the AAVance Clinical Trial Evaluating LYS-SAF302 in Patients with MPS IIIA (Businesswire)
25.09.20		Lysogene Reports First Half 2020 Financial Results and Provides Operational Update (Businesswire)
01.07.20		Lysogene Announces a Research Collaboration With the Weizmann Institute of Science (Businesswire)
05.06.20		Lysogene announces important updates on AAVance phase 2/3 clinical trial with LYS-SAF302 in MPS IIIA (Businesswire)
14.05.20		Lysogene Announces Presentations at Upcoming Meetings (Businesswire)
29.04.20		Lysogene Reports Its Cash Position as of 31 March 2020 (Businesswire)
22.04.20		Lysogene Reports Full Year 2019 Financial Results and Provides Operational Update (Businesswire)
16.03.20		Lysogene Announces the Date of Its 2020 General Shareholders’ Meeting and Amends Its Financial Calendar (Businesswire)
25.02.20		Lysogene Receives FDA Fast Track Designation for LYS-SAF302 Gene Therapy in MPS IIIA (Businesswire)
17.02.20		Lysogene Reports its Cash Position as of 31 December 2019 (Businesswire)
11.02.20		Lysogene Announces Presentations at Upcoming 16th WORLDSymposium™ on Lysosomal Diseases (Businesswire)
24.01.20		Lysogene Announces Its Corporate Agenda For 2020 (Businesswire)
18.12.19		Lysogene Announces the Publication of an Article in the Scientific Journal "Molecular Therapy Methods & Clinical Development” Demonstrating the Potential of Its Drug Candidate LYS-SAF302 (Businesswire)
20.11.19		Lysogene Reports its Cash Position as of 30 September 2019 (Businesswire)
17.10.19		Lysogene Appoints Mr. Stéphane Durant des Aulnois as Chief Financial Officer (Businesswire)
30.09.19		Lysogene Reports First Half 2019 Financial Results and Provides Operational Update (Businesswire)
26.09.19		Lysogene Announces the Appointment of Carole Deffez as New Independent Board Director (Businesswire)
05.09.19		Lysogene: A Pivotal Year 2019 for Lysogene’s MPS IIIA Phase 2-3 Clinical Trial (Businesswire)
18.07.19		Lysogene Establishes Scientific Advisory Board with International Experts in CNS Gene Therapy (Businesswire)
05.09.18		Lysogene Announces FDA approval of IND Application to Initiate Phase 2-3 Clinical Trial in MPS IIIA (Businesswire)
15.05.18		Lysogene Announces the Nomination of Dr Ralph Laufer as Chief Scientific Officer and Member of the Executive Team (Businesswire)
06.02.18		Lysogene Gets PIP Green Light from European Medicines Agency on MPS IIIA Pivotal Study; Paving Way for Clinical Trial Application Approvals (Businesswire)
01.02.18		Lysogene to Present Five Year Clinical Data in MPS IIIA at the 14th Annual WORLDSymposiumTM (Businesswire)
15.01.18		Lysogene Reports Fourth Quarter 2017 Financial Information (Businesswire)
21.12.17		Lysogene Holds First Clinical Advisory Board Meeting in Mucopolysaccharidosis Type IIIA (MPS IIIA) and GM1 Gangliosidosis (Businesswire)
18.10.17		Lysogene Announces Company Presentations at Upcoming Scientific Conferences (Businesswire)
16.10.17		Lysogene: Financial Information for the Third Quarter of 2017 (Businesswire)
05.10.17		Lysogene to Host Key Opinion Leader Meeting on Gene Therapy for Patients with Sanfilippo Syndrome Type A in New York City (Businesswire)
04.10.17		Lysogene Announces Company Presentations at October & November Investor Conferences (Businesswire)
21.09.17		Lysogene Holds First Parent Advisory Board in MPS IIIA (Businesswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

Solana Kurs Prognose: Jetzt einsteigen und Millionär werden?

Pierer Mobility-Aktie mit zweistelligem Kurssprung: KTM AG wird fortgeführt - Eigenverwaltung bleibt

Bullishe Aussichten: Das erwartet JPMorgan für den Goldpreis in 2025

Mayr-Melnhof startet im kommenden Jahr Aktienrückkauf - Aktie gewinnt deutlich

Lilium-Aktie zündet Kursrakete: Lilium kann neuen Investor von sich überzeugen

Bitcoin Kurs Prognose: BTC verliert 10 Prozent, jetzt schnell verkaufen?

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	26.12.2024 22:55
Kaufwert:	EUR
	Hinzufügen Speichern